Literature DB >> 35082865

Combined Aortic and Mitral Valve Stenosis in Mucopolysaccharidosis Syndrome Type I-S: A Report of a Rare Case.

Hakimeh Sadeghian1, Afsaneh Sadeghian1, Bahareh Eslami1, Seyed Hesameddin Abbasi1,2, Masoumeh Lotfi-Tokaldany1.   

Abstract

Mucopolysaccharidosis (MPS) syndrome is an inherited metabolic disorder. In more than half of the patients with MPS syndrome, heart valve involvement is reported; however, combined aortic and mitral valve stenosis in MPS syndrome type I-S is very rare. We describe a 39-year-old man with severe mitral and aortic valve stenosis due to MPS syndrome type I-S. Transthoracic and transesophageal echocardiography revealed severe thickening and calcification in the aortic and mitral valves with severe left ventricular hypertrophy. The coronary arteries were normal in angiography.
Copyright © 2021 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences.

Entities:  

Keywords:  Aortic valve stenosis; Heart valve diseases; Mitral valve stenosis; Mucopolysaccharidosis I

Year:  2021        PMID: 35082865      PMCID: PMC8728857          DOI: 10.18502/jthc.v16i1.6598

Source DB:  PubMed          Journal:  J Tehran Heart Cent        ISSN: 1735-5370


Introduction

Mucopolysaccharidosis (MPS) syndrome is a hereditary disorder of proteoglycan-degrading enzymes,[1] resulting in the lysosomal accumulation of sulfated glycosaminoglycans (GAGs) in many tissues. Based on biochemical, clinical, and genetic aspects, 9 subtypes are defined for MPS syndrome. Cardiac involvement has been reported as a common and early feature of MPS syndrome subtypes I, II, and VI.[2] Cardiac involvement is present in 50% to 76% of patients with Scheie syndrome. The mitral valve is the most commonly involved valve (42% clinically symptomatic), followed by the aortic valve (20%). A combination of mitral and aortic valve lesions associated with MPS syndrome type I-S (a mild form of MPS syndrome I) is very rare.[3], [4]

Case Report

A 39-year-old man presented with a history of fatigue and dyspnea of 4 years’ duration. In the patient’s past medical history, based on clinical features such as joint stiffness, corneal opacity, hepatosplenomegaly, the urinary excretion of MPS, and positive family history, MPS syndrome type I-S had been confirmed when he was 20. Skeletal deformities such as thoracolumbar kyphosis, pigeon chest, and joint stiffness had occurred progressively since he was 7 years old. One year before his referral to us, he lost his visual perception in the right eye. He was short (150 cm), and his left eye was hyperopic. He was of normal intelligence and had a university degree. The first echocardiography (about 5 years earlier) revealed moderate mitral valve stenosis, based on which his cardiologist recommended medical treatment and yearly echocardiographic evaluations. Despite medical treatment, the patient’s symptoms exacerbated and he experienced several episodes of syncope due to ventricular fibrillation, which resulted in multiple coronary care unit admissions during the year prior to his referral. The patient was referred to Tehran Heart Center for further evaluation. Electrocardiographic findings revealed normal sinus rhythm with the right bundle branch block. On physical examination, the notable findings were short stature, claudication, and joint stiffness. Auscultation of the heart revealed diastolic rumbles in the apex and systolic ejection murmurs at the aortic area with early diastolic murmurs. Two-dimensional (2D) transthoracic and transesophageal echocardiography demonstrated a non-dilated, albeit concentrically hypertrophied, left ventricle with normal global and segmental systolic function (ejection fraction = 55%). Transthoracic echocardiography showed that the left atrium was mildly dilated without any clot. Both mitral leaflets were very thick (Figure 1) with severe stenosis (mean diastolic gradient = 7 mmHg and peak diastolic gradient =17 mmHg) (Figure 2), and there was mild regurgitation. The mitral valve area was 0.9 cm² via planimetry (Figure 3) with a score of 10 to 11. The aortic valve was severely thick and stenotic (peak systolic gradient = 152 mmHg and mean systolic gradient = 85 mmHg) (Figure 4) with moderately severe regurgitation. According to 2D transesophageal echocardiography, the aortic valve area was 0.8 cm² via the continuity equation method and 0.7 cm2 via the direct planimetry method (Figure 5). Additionally, the annulus was 18 mm in diameter. Further, the right ventricle was normal in size and function, the tricuspid valve had trivial regurgitation, and pulmonary artery pressure was 40 mmHg.
Figure 1

Transthoracic echocardiography (parasternal long-axis view) shows LV hypertrophy and the involvement of the mitral leaflets (arrow) and the subvalvular apparatus by deposits in a patient with mucopolysaccharidosis syndrome type I-S.

Figure 2

Transthoracic echocardiography (apical 4-chamber view) by continuous-wave Doppler shows a mean mitral valve gradient of 7 mmHg and a mitral valve area of 1.3 cm2 via the pressure half-time method.

Figure 3

Transthoracic echocardiography (short-axis view) shows an MVA of 0.9 cm2 (arrow) via the planimetry method.

Figure 4

Transthoracic echocardiography (apical 5-chamber view) by continuous-wave Doppler shows a peak aortic valve gradient of 152 mmHg.

Figure 5

Transesophageal echocardiography (short-axis view) shows an aortic valve area of 0.7 cm2 (arrow) via the direct planimetry method.

Coronary angiography revealed normal findings, and pressure gradients, measured through cardiac catheterization, confirmed the echocardiography-based diagnosis. Aortic and mitral valve replacement, postoperative reevaluation for syncope, and implantable cardioverter-defibrillator implantation, if needed, were recommended. Transthoracic echocardiography (parasternal long-axis view) shows LV hypertrophy and the involvement of the mitral leaflets (arrow) and the subvalvular apparatus by deposits in a patient with mucopolysaccharidosis syndrome type I-S. RV, Right ventricle; LV, Left ventricle; LA, Left atrium Transthoracic echocardiography (apical 4-chamber view) by continuous-wave Doppler shows a mean mitral valve gradient of 7 mmHg and a mitral valve area of 1.3 cm2 via the pressure half-time method. Transthoracic echocardiography (short-axis view) shows an MVA of 0.9 cm2 (arrow) via the planimetry method. MVA, Mitral valve area Transthoracic echocardiography (apical 5-chamber view) by continuous-wave Doppler shows a peak aortic valve gradient of 152 mmHg. Transesophageal echocardiography (short-axis view) shows an aortic valve area of 0.7 cm2 (arrow) via the direct planimetry method.

Discussion

MPS syndrome is a heterogeneous group of inheritable storage diseases due to lysosomal enzyme deficiencies, which destroy GAGs. Enzyme deficiency results in the tissue accumulation and excessive urinary excretion of GAGs, various degrees of progressive mental and physical deterioration, and premature death in severe forms. In MPS syndrome type-I, as an autosomal recessive disorder, acid hydrolase-α-l-iduronidase deficiency leads to the intracellular accumulation of heparan sulfate and dermatan sulfate, a hallmark of MPS syndrome type-I.[5] Scheie syndrome or MPS syndrome type I-S is characterized by joint stiffness, cardiac disease, and corneal clouding.[6] Other clinical manifestations of Scheie syndrome are short stature, short neck, claw hands, and special features such as a high forehead, a flat nasal bridge, and skeletal and joint malformations. A diagnostic point for MPS syndrome type I-S (in contrast to MPS syndrome type I-H) is normal intelligence and behavior in these patients.[1], [3] Yearly echocardiographic evaluations in patients with MPS syndrome are recommended.[7] The main heart disease in MPS syndrome is valvular abnormalities, which occur at a young age[8] and most commonly affect the mitral valve, followed by the tricuspid and aortic valves. Reports on combined aortic and mitral valve stenosis are very rare.[3], [4] Valve dysfunction includes valve fibrosis, calcification, and thickening due to GAGs accumulation.[3] Meanwhile, lysosomal GAG deposits in the myocardium lead to myocardial hypertrophy and subsequently diastolic dysfunction.[1] Based on autopsy reports, coronary artery disease has also been described in patients with MPS syndrome.[7] In our case, coronary angiography revealed normal coronary arteries. Because of irregular valve structure due to GAG accumulation, patients with significant left-sided heart valve disease require surgical valve replacement.[3]

Conclusion

Our patient was an adult man, a known case of MPS syndrome type I-S with the clinical manifestations of Scheie syndrome, who presented with severe left heart valve involvement (aortic and mitral stenosis) and was candidated for surgery.
  8 in total

1.  Combined aortic and mitral stenosis in mucopolysaccharidosis type I-S (Ullrich-Scheie syndrome).

Authors:  T A Fischer; H A Lehr; U Nixdorff; J Meyer
Journal:  Heart       Date:  1999-01       Impact factor: 5.994

2.  Combined aortic and mitral valve replacement in an adult with Scheie's disease.

Authors:  S M Butman; L Karl; J G Copeland
Journal:  Chest       Date:  1989-07       Impact factor: 9.410

3.  Echocardiographic study of paediatric patients with mucopolysaccharidosis.

Authors:  Gabriela N Leal; Ana C de Paula; Cláudio Leone; Chong A Kim
Journal:  Cardiol Young       Date:  2010-04-26       Impact factor: 1.093

4.  Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I.

Authors:  Kenta Sugiura; Toru Kubo; Yuri Ochi; Yuichi Baba; Takayoshi Hirota; Naohito Yamasaki; Hiroaki Kitaoka
Journal:  Mol Genet Metab Rep       Date:  2020-10-20

5.  Bone marrow transplantation for feline mucopolysaccharidosis I.

Authors:  N Matthew Ellinwood; Marie-Anne Colle; Margaret A Weil; Margret L Casal; Charles H Vite; Staci Wiemelt; Christopher W Hasson; Thomas M O'Malley; Xingxuan He; Ulana Prociuk; Lucie Verot; John R Melniczek; Anne Lannon; Gustavo D Aguirre; Van W Knox; Sydney M Evans; Marie T Vanier; Edward H Schuchman; Steven U Walkley; Mark E Haskins
Journal:  Mol Genet Metab       Date:  2007-05-07       Impact factor: 4.797

6.  Surgical treatment for mitral stenosis in Scheie's syndrome: mucopolysaccharidosis type I-S.

Authors:  Katsukiyo Kitabayashi; Goro Matsumiya; Hajime Ichikawa; Hajime Matsue; Kazuo Shimamura; Yoshiki Sawa
Journal:  Ann Thorac Surg       Date:  2007-08       Impact factor: 4.330

7.  Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment.

Authors:  Roberto Giugliani; Andressa Federhen; Maria Verônica Muñoz Rojas; Taiane Vieira; Osvaldo Artigalás; Louise Lapagesse Pinto; Ana Cecília Azevedo; Angelina Acosta; Carmen Bonfim; Charles Marques Lourenço; Chong Ae Kim; Dafne Horovitz; Denize Bonfim; Denise Norato; Diane Marinho; Durval Palhares; Emerson Santana Santos; Erlane Ribeiro; Eugênia Valadares; Fábio Guarany; Gisele Rosone de Lucca; Helena Pimentel; Isabel Neves de Souza; Jordão Correa; José Carlos Fraga; José Eduardo Goes; José Maria Cabral; José Simionato; Juan Llerena; Laura Jardim; Liane Giuliani; Luiz Carlos Santana da Silva; Mara L Santos; Maria Angela Moreira; Marcelo Kerstenetzky; Márcia Ribeiro; Nicole Ruas; Patricia Barrios; Paulo Aranda; Rachel Honjo; Raquel Boy; Ronaldo Costa; Carolina Souza; Flavio F Alcantara; Silvio Gilberto A Avilla; Simone Fagondes; Ana Maria Martins
Journal:  Genet Mol Biol       Date:  2010-12-01       Impact factor: 1.771

8.  The natural history of MPS I: global perspectives from the MPS I Registry.

Authors:  Michael Beck; Pamela Arn; Roberto Giugliani; Joseph Muenzer; Torayuki Okuyama; John Taylor; Shari Fallet
Journal:  Genet Med       Date:  2014-03-27       Impact factor: 8.822

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.